Targeted therapies in epithelial ovarian cancer

Cancers

Volumn 2, Issue 1, 2010, Pages 88-113

  Dean, Emma ^a   El Helw, Loaie ^a   Hasan, Jurjees ^a  

^a CHRISTIE HOSPITAL   (United Kingdom)

Author keywords

Ovarian cancer; Targeted therapy

Indexed keywords

6 [4 (4 ETHYL 1 PIPERAZINYLMETHYL)PHENYL] 4 (ALPHA METHYLBENZYLAMINO) 7H PYRROLO[2,3 D]PYRIMIDINE; AFLIBERCEPT; ALANINE AMINOTRANSFERASE; ANGIOGENESIS INHIBITOR; BEVACIZUMAB; CARBOPLATIN; CEDIRANIB; CISPLATIN; CYCLOPHOSPHAMIDE; CYTOTOXIC AGENT; DOCETAXEL; EMD 7200; ERLOTINIB; GEFITINIB; IMATINIB; IMMUNOLOGIC AGENT; MATUZUMAB; NAVELBINE; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE INHIBITOR; PACLITAXEL; PAZOPANIB; PERTUZUMAB; PLACEBO; PROTEIN TYROSINE KINASE INHIBITOR; SORAFENIB; SUNITINIB; TOPOTECAN; TRASTUZUMAB; UNCLASSIFIED DRUG; UNINDEXED DRUG; VASCULAR TARGETING AGENT; VASCULOTROPIN INHIBITOR;

ABDOMINAL PAIN; ACUTE PANCREATITIS; ANTINEOPLASTIC ACTIVITY; ARTERY THROMBOSIS; ASCITES; BLEEDING; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER RECURRENCE; CANCER RELAPSE; CANCER RESISTANCE; CANCER SURVIVAL; CHEMOTHERAPY INDUCED EMESIS; CHYLOUS ASCITES; CLEAR CELL CARCINOMA; CYTOPENIA; CYTOREDUCTIVE SURGERY; DIARRHEA; DIGESTIVE SYSTEM PERFORATION; DRUG DOSE REDUCTION; DRUG ERUPTION; DRUG HYPERSENSITIVITY; DRUG INDUCED HEADACHE; DRUG MECHANISM; DRUG MEGADOSE; DRUG SAFETY; DYSPNEA; FATIGUE; FEBRILE NEUTROPENIA; GASTROINTESTINAL TOXICITY; HAND FOOT SYNDROME; HUMAN; HYPERTENSION; INTESTINE OBSTRUCTION; KIDNEY CANCER; LETHARGY; LIVER FUNCTION TEST; LOADING DRUG DOSE; LOW DRUG DOSE; LUNG CANCER; MAINTENANCE THERAPY; METABOLIC DISORDER; MOLECULAR BIOLOGY; MOLECULAR IMAGING; MONOTHERAPY; MULTIPLE CYCLE TREATMENT; MYALGIA; NAUSEA; NAUSEA AND VOMITING; NEUROPATHY; NEUTROPENIA; NONHUMAN; OVARY CARCINOMA; OVERALL SURVIVAL; PAIN; PERITONEUM CANCER; PLEURA EFFUSION; POSTERIOR REVERSIBLE ENCEPHALOPATHY SYNDROME; PROGRESSION FREE SURVIVAL; PROTEINURIA; RECURRENT CANCER; REVIEW; SIDE EFFECT; SURVIVAL RATE; SURVIVAL TIME; THROMBOCYTOPENIA; TRACHEOESOPHAGEAL FISTULA; TREATMENT RESPONSE; UTERINE TUBE CARCINOMA; VENOUS THROMBOEMBOLISM; WOUND HEALING IMPAIRMENT;

EID: 79952162837     PISSN: None     EISSN: 20726694     Source Type: Journal    
DOI: 10.3390/cancers2010088     Document Type: Review

References (127)

1. Parkin, D.M.; Bray, F.; Ferlay, J.; Pisani, P. Global cancer statistics, 2002. CA Cancer J. Clin. 2005, 55, 74-108.
2. Jemal, A.; Siegel, R.; Ward, E.; Hao, Y.; Xu, J.; Murray, T.; Thun, M.J. Cancer statistics, 2008. CA Cancer J. Clin. 2008, 58, 71-96.
3. Dinh, P.; Harnett, P.; Piccart-Gebhart, M.J.; Awada, A. New therapies for ovarian cancer: cytotoxics and molecularly targeted agents. Crit. Rev. Oncol. Hematol. 2008, 67, 103-112.
4. Greenlee, R.T.; Hill-Harmon, M.B.; Murray, T.; Thun, M. Cancer statistics, 2001. CA Cancer J. Clin. 2001, 51, 15-36.
5. Ozols, R.F.; Bundy, B.N.; Greer, B.E.; Fowler, J.M.; Clarke-Pearson, D.; Burger, R.A.; Mannel, R.S.; DeGeest, K.; Hartenbach, E.M; Baergen, R. Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer: a Gynecologic Oncology Group study. J. Clin. Oncol. 2003, 21, 3194-3200.
6. Biagi, J.J.; Eisenhauer, E.A. Systemic treatment policies in ovarian cancer: the next 10 years. Int. J. Gynecol. Cancer 2003, 13(Suppl 2), 231-240.
7. Sandercock, J.; Parmar, M.K.; Torri, V.; Qian, W. First-line treatment for advanced ovarian cancer: paclitaxel, platinum and the evidence. Br. J. Cancer 2002, 87, 815-824.
8. Cannistra, S.A. Cancer of the ovary. N. Engl. J. Med. 2004, 351, 2519-2529.
9. Agarwal, R.; Kaye, S.B. Ovarian cancer: strategies for overcoming resistance to chemotherapy. Nat. Rev. Cancer 2003, 3, 502-516.
10. Demetri, G.D.; von Mehren, M.; Blanke, C.D.; van den Abbeele, A.D.; Eisenberg, B.; Roberts, P.J.; Heinrich, M.C.; Tuveson, D.A.; Singer, S.; Janicek, M. et al. Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. N. Engl. J. Med. 2002, 347, 472-480.
11. Hurwitz, H.; Fehrenbacher, L.; Novotny, W.; Cartwright, T.; Hainsworth, J.; Heim, W.; Berlin, J.; Baron, A.; Griffing, S.; Holmgren, E., et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N. Engl. J. Med. 2004, 350, 2335-2342.
12. Zondor, S.D.; Medina, P.J. Bevacizumab: an angiogenesis inhibitor with efficacy in colorectal and other malignancies. Ann. Pharmacother. 2004, 38, 1258-1264.
13. Miller, K.; Wang, M.; Gralow, J.; Dickler, M.; Cobleigh, M.; Perez, E.A.; Shenkier, T.; Cella, D.; Davidson, N.E. Paclitaxel plus Bevacizumab versus Paclitaxel Alone for Metastatic Breast Cancer. N. Engl. J. Med. 2007, 357, 2666-2676.
14. Sandler, A.; Herbst, R. Combining Targeted Agents: Blocking the Epidermal Growth Factor and Vascular Endothelial Growth Factor Pathways. Clin. Cancer Res. 2006, 12, 4421-4425s.
15. Llovet, J.; Ricci, S.; Mazzaferro, V.; Hilgard, P.; Raoul, J.; Zeuzern, S.; Poulin-Costello, M.; Moscovici, M.; Voliotis, D.; Bruix, J. Sorafenib improves survival in advanced Hepatocellular Carcinoma (HCC): Result of a Phase III randomised placebo-controlled trial (SHARP trial). J. Clin. Oncol. 2007, 25 (18S), Abstr. LBA1.
16. Escudier, B.; Eisen, T.; Stadler, W.M.; Szczylik, C.; Oudard, S.; Siebels, M.; Negrier, S.; Chevreau, C.; Solska, E.; Desai, A.A., et al. Sorafenib in advanced clear-cell renal-cell carcinoma. N. Engl. J. Med. 2007, 356, 125-134.
17. Motzer, R.J.; Hutson, T.E.; Tomczak, P.; Michaelson, M.D.; Bukowski, R.M.; Rixe, O.; Oudard, S.; Negrier, S.; Szczylik, C.; Kim, S.T., et al. Sunitinib versus interferon alfa in metastatic renalcell carcinoma. N. Engl. J. Med. 2007, 356, 115-124.
18. Martin, L.; Schilder, R. Novel approaches in advancing the treatment of epithelial ovarian cancer: the role of angiogenesis inhibition. J. Clin. Oncol. 2007, 25, 2894-901.
19. Stone, P.J.; Goodheart, M.J.; Rose, S.L.; DeYoung, B.R.; Buller, R.E. The influence of microvessel density on ovarian carcinogenesis. Gynecol. Oncol. 2003, 90, 566-571.
20. Goodheart, M.J.; Ritchie, J.M.; Rose, S.L.; Fruehauf, J.P.; DeYoung, B.R.; Buller, R.E. The relationship of molecular markers of p53 function and angiogenesis to prognosis of stage I epithelial ovarian cancer. Clin. Cancer Res. 2005, 11, 3733-3742.
21. Hefler, L.A.; Mustea, A.; Konsgen, D.; Concin, N.; Tanner, B.; Strick, R.; Heinze, G.; Grimm, C.; Schuster, E.; Tempfer, C., et al. Vascular endothelial growth factor gene polymorphisms are associated with prognosis in ovarian cancer. Clin. Cancer Res. 2007, 13, 898-901.
22. Byrne, A.T.; Ross, L.; Holash, J.; Nakanishi, M.; Hu, L.; Hofmann, J.I.; Yancopoulos, G.D.; Jaffe, R.B. Vascular endothelial growth factor-trap decreases tumor burden, inhibits ascites, and causes dramatic vascular remodeling in an ovarian cancer model. Clin. Cancer Res. 2003, 9, 5721-5728.
23. Schumacher, J.J.; Dings, R.P.; Cosin, J.; Subramanian, I.V.; Auersperg, N.; Ramikrishnan, S. Modulation of angiogenic phenotype alters tumorigenicity in rat ovarian epithelial cells. Cancer Res. 2007, 67, 3683-3690.
24. Spannuth, W.A.; Sood, A.K.; Coleman, R.L. Angiogenesis as a strategic target for ovarian cancer therapy. Nat. Clin. Pract. Oncol. 2008, 5, 194-204.
25. Rosa, D.D.; Clamp, A.R.; Collinson, F.; Jayson, G.C. Antiangiogenic therapy for ovarian cancer. Curr. Opin. Oncol. 2007, 19, 497-505.
26. Mesiano, S.; Ferrara, N.; Jaffe, R.B. Role of vascular endothelial growth factor in ovarian cancer: inhibition of ascites formation by immunoneutralization. Am. J. Pathol. 1998, 153, 1249-1256.
27. Hu, L.; Hofmann, J.; Lu, Y.; Mills, G.B.; Jaffe, R.B. Inhibition of phosphatidylinositol 3'-kinase increases efficacy of paclitaxel in vitro and in vivo ovarian cancer models. Cancer Res. 2002, 62, 1087-1092.
28. Mabuchi, S.; Terai, Y.; Morishige, K.; Tanabe-Kimura, A.; Sasaki, H.; Kanemura, M.; Tsunetoh, S.; Tanaka, Y.; Sakata, M.; Burger, R.A., et al. Maintenance treatment with bevacizumab prolongs survival in an in vivo ovarian cancer model. Clin. Cancer Res. 2008, 14, 7781-7789.
29. Cannistra, S.A.; Matulonis, U.A.; Penson, R.T.; Hambleton, J.; Dupont, J.; Mackey, H.; Douglas, J.; Burger, R.A.; Armstrong, D.; Wenham, R., et al. Phase II study of bevacizumab in patients with platinum-resistant ovarian cancer or peritoneal serous cancer. J. Clin. Oncol. 2007, 25, 5180-5186.
30. Numnum, T.M.; Rocconi, R.P.; Whitworth, J.; Barnes, M.N. The use of bevacizumab to palliate symptomatic ascites in patients with refractory ovarian carcinoma. Gynecol. Oncol. 2006, 102, 425-428.
31. Monk, B.J.; Han, E.; Josephs-Cowan, C.A.; Pugmire, G.; Burger, R.A. Salvage bevacizumab (rhuMAB VEGF)-based therapy after multiple prior cytotoxic regimens in advanced refractory epithelial ovarian cancer. Gynecol. Oncol. 2006, 102, 140-144.
32. Burger, R.A.; Sill, M.W.; Monk, B.J.; Greer, B.E.; Sorosky, J.I. Phase II trial of bevacizumab in persistent or recurrent epithelial ovarian cancer or primary peritoneal cancer: a Gynecologic Oncology Group Study. J. Clin. Oncol. 2007, 25, 5165-5171.
33. Garcia, A.A.; Hirte, H.; Fleming, G.; Yang, D.; Tsao-Wei, D.D.; Roman, L.; Groshen, S.; Swenson, S.; Markland, F.; Gandara, D., et al. Phase II clinical trial of bevacizumab and low-dose metronomic oral cyclophosphamide in recurrent ovarian cancer: a trial of the California, Chicago, and Princess Margaret Hospital phase II consortia. J. Clin. Oncol. 2008, 26, 76-82.
34. Wright, J.D.; Secord, A.A.; Numnum, T.M.; Rocconi, R.P.; Powell, M.A.; Berchuck, A.; Alvarez, R.D.; Gibb, R.K.; Trinkaus, K.; Rader, J.S., et al. A multi-institutional evaluation of factors predictive of toxicity and efficacy of bevacizumab for recurrent ovarian cancer. Int. J. Gynecol. Cancer 2008, 18, 400-406.
35. Fukumura, D.; Jain, R.K. Tumor microenvironment abnormalities: causes, consequences, and strategies to normalize. J. Cell Biochem. 2007, 101, 937-949.
36. Hanahan, D.; Bergers, G.; Bergsland, E. Less is more, regularly: metronomic dosing of cytotoxic drugs can target tumor angiogenesis in mice. J. Clin. Invest. 2000, 105, 1045-1047.
37. Klement, G.; Baruchel, S.; Rak, J.; Man, S.; Clark, K.; Hicklin, D.J.; Bohlen, P.; Kerbel, R.S. Continuous low-dose therapy with vinblastine and VEGF receptor-2 antibody induces sustained tumor regression without overt toxicity. J. Clin. Invest. 2000, 105, R15-R24.
38. Kamat, A.A.; Kim, T.J.; Landen, C.N., Jr.; Lu, C.; Han, L.Y.; Lin, Y.G.; Merritt, W.M.; Thaker, P.H.; Gershenson, D.M.; Bischoff, F.Z., et al. Metronomic chemotherapy enhances the efficacy of antivascular therapy in ovarian cancer. Cancer Res. 2007, 67, 281-288.
39. Chura, J.C.; van Iseghem, K.; Downs, L.S., Jr.; Carson, L.F.; Judson, P.L. Bevacizumab plus cyclophosphamide in heavily pretreated patients with recurrent ovarian cancer. Gynecol. Oncol. 2007, 107, 326-330.
40. Micha, J.P.; Goldstein, B.H.; Rettenmaier, M.A.; Genesen, M.; Graham, C.; Bader, K.; Lopez, K.L.; Nickle, M.; Brown, J.V., III. A phase II study of outpatient first-line paclitaxel, carboplatin, and bevacizumab for advanced-stage epithelial ovarian, peritoneal, and fallopian tube cancer. Int. J. Gynecol. Cancer 2007, 17, 771-776.
41. Campos, S.M.; Dizon, D.S.; Cannistra, S.A.; Roche, M.; Krasner, C.N.; Berlin, S.T.; Horowitz, N.S.; DiSilvestro, P.; Matulonis, U.A.; Penson, R.T. Safety of maintenance bevacizumab after first-line chemotherapy for advanced ovarian and müllerian cancers. J. Clin. Oncol. 2007, 25(18S), Abstr. 5517.
42. Kabbinavar, F.; Hurwitz, H.I.; Fehrenbacher, L.; Meropol, N.J.; Novotny, W.F.; Lieberman, G.; Griffing, S.; Bergsland, E. Phase II, Randomized Trial Comparing Bevacizumab Plus Fluorouracil (FU)/Leucovorin (LV) With FU/LV Alone in Patients With Metastatic Colorectal Cancer. J. Clin. Oncol. 2003, 21, 60-65.
43. Tew, W.P.; Colombo, N.; Ray-Coquard, I.; Oza, A.; del Campo, J.; Scambia, G.; Spriggs, D. VEGF-Trap for patients (pts) with recurrent platinum-resistant epithelial ovarian cancer (EOC): Preliminary results of a randomized, multicenter phase II study. J. Clin. Oncol. 2007, 25(18S), Abstr. 5508.
44. Biagi, J.J.; Oza, A.M.; Grimshaw, R.; Ellard, S.L.; Lee, U.; Sederias, J.; Ivy, S.P.; Eisenhauer, E.A. A phase II study of sunitinib (SU11248) in patients (pts) with recurrent epithelial ovarian, fallopian tube or primary peritoneal carcinoma - NCIC CTG IND 185. J. Clin. Oncol. 2008, 26(suppl), Abstr. 5522.
45. Matulonis, U.A.; Berlin, S.T.; Krasner, C.N.; Tyburski, K.; Lee, J.; Roche, M.; Ivy, S.P.; Lenahan, C.; King, M.; Penson, R.T. Cediranib (AZD2171) is an active agent in recurrent epithelial ovarian cancer. J. Clin. Oncol. 2008, 26(suppl), Abstr. 5501.
46. Matei, D.; Sill, M.W.; DeGeest, K.; Bristow, R.E. Phase II trial of sorafenib in persistent or recurrent epithelial ovarian cancer (EOC) or primary peritoneal cancer (PPC): A Gynecologic Oncology Group (GOG) study. J. Clin. Oncol. 2008, 26(suppl), Abstr. 5537.
47. Friedlander, M.; Hancock, K.C.; Benigno, B.; Rischin, D.; Messing, M.; Stringer, C.A.; Tay, E.H.; Kathman, S.; Matthys, G.; Lager, J.J. Pazopanib (GW786034) is active in women with advanced epithelial ovarian, fallopian tube and peritoneal cancers: Initial results of a phase II study. J. Clin. Oncol. 2007, 25(18S), Abstr. 5561.
48. Coleman, R.L.; Broaddus, R.R.; Bodurka, D.C.; Wolf, J.K.; Burke, T.W.; Kavanagh, J.J.; Levenback, C.F.; Gershenson, D.M. Phase II trial of imatinib mesylate in patients with recurrent platinum- and taxane-resistant epithelial ovarian and primary peritoneal cancers. Gynecol. Oncol. 2006, 101, 126-131.
49. Posadas, E.M.; Kwitkowski, V.; Kotz, H.L.; Espina, V.; Minasian, L.; Tchabo, N.; Premkumar, A.; Hussain, M.M.; Chang, R.; Steinberg, S.M., et al. A prospective analysis of imatinib-induced c-KIT modulation in ovarian cancer: a phase II clinical study with proteomic profiling. Cancer 2007, 110, 309-317.
50. Hirte, H.W.; Vidal, L.; Fleming, G.F.; Sugimoto, A.K.; Morgan, R.J.; Biagi, J.J.; Wang, L.; McGill, S.; Ivy, S.P.; Oza, A.M. A phase II study of cediranib (AZD2171) in recurrent or persistent ovarian, peritoneal or fallopian tube cancer: Final results of a PMH, Chicago and California consortia trial. J. Clin. Oncol. 2008, 26(suppl), Abstr. 5521.
51. Azad, N.S.; Posadas, E.M.; Kwitkowski, V.E.; Steinberg, S.M.; Jain, L.; Annunziata, C.M.; Minasian L.; Sarosy, G.; Kotz, H.L.; Premkumar, A., et al. Combination targeted therapy with sorafenib and bevacizumab results in enhanced toxicity and antitumor activity. J. Clin. Oncol. 2008, 26, 3709-3714.
52. Sandler, A.; Herbst, R. Combining targeted agents: blocking the epidermal growth factor and vascular endothelial growth factor pathways. Clin. Cancer Res. 2006, 12, 4421s-4425s.
53. Nimeiri, H.S.; Oza, A.M.; Morgan, R.J.; Friberg, G.; Kasza, K.; Faoro, L.; Salgia, R.; Stadler, W.M.; Vokes, E.E.; Fleming, G.F. Efficacy and safety of bevacizumab plus erlotinib for patients with recurrent ovarian, primary peritoneal, and fallopian tube cancer: a trial of the Chicago, PMH, and California Phase II Consortia. Gynecol. Oncol. 2008, 110, 49-55.
54. Hecht, J.R.; Mitchell, E.; Chidiac, T.; Scroggin, C.; Hagenstad, C.; Spigel, D.; Marshall, J.; Cohn, A.; McCollum, D.; Stella, P et al. A randomized phase IIIB trial of chemotherapy, bevacizumab, and panitumumab compared with chemotherapy and bevacizumab alone for metastatic colorectal cancer. J. Clin. Oncol. 2009, 27, 672-680.
55. Nathan, P.D.; Judson, I.; Padhani, A.; Harris, A.; Carden, C.P.; Smythe, J.; Collins, D.; Leach, M.; Walicke, P.; Rustin, G.J. A phase I study of combretastatin A4 phosphate (CA4P) and bevacizumab in subjects with advanced solid tumors. J. Clin. Oncol. 2008, 26(suppl), Abstr. 3550.
56. Shaked, Y.; Ciarrocchi, A.; Franco, M.; Lee, C.R.; Man, S.; Cheung, A.M.; Hicklin, D.J.; Chaplin, D.; Foster, F.S.; Benezra, R. et al. Therapy-induced acute recruitment of circulating endothelial progenitor cells to tumors. Science 2006, 313, 1785-1787.
57. Gridelli, C.; Rossi, A.; Maione, P.; Rossi, E.; Castaldo, V.; Sacco, P.C.; Colantuoni, G. Vascular disrupting agents: a novel mechanism of action in the battle against non-small cell lung cancer. Oncologist 2009, 14, 612-620.
58. Zweifel, M.; Jayson, G.; Reed, N.; Osborne, R.; Hassan, B.; Shrreves, G.; Poupard, L.; Walicke, A.; Balkissoon, J.; Chaplin, D., et al. Combretastatin A-4 phosphate (CA4P) carboplatin and paclitaxel in patients with platinum-resistant ovarian cancer: Final phase II trial results. J. Clin. Oncol. 2009, 27(15S), Abstr. 5502.
59. Hapani, S.; Chu, D.; Wu, S. Risk of gastrointestinal perforation in patients with cancer treated with bevacizumab: a meta-analysis. Lancet Oncol. 2009, 10, 559-568.
60. Han, E.S.; Monk, B.J. What is the risk of bowel perforation associated with bevacizumab therapy in ovarian cancer? Gynecol. Oncol. 2007, 105, 3-6.
61. Zhu, X.; Wu, S.; Dahut, W.L.; Parikh, C.R. Risks of proteinuria and hypertension with bevacizumab, an antibody against vascular endothelial growth factor: Systematic review and meta-analysis. Am. J. Kidney Dis. 2007, 49, 186-193.
62. Yang, J.C.; Haworth, L.; Sherry, R.M.; Hwu, P.; Schwartzentruber, D.J.; Topalian, S.L.; Steinberg, S.M.; Chen, H.X.; Rosenberg, S.A. A randomized trial of bevacizumab, an antivascular endothelial growth factor antibody, for metastatic renal cancer. N. Engl. J. Med. 2003, 349, 427-434.
63. Veronese, M.L.; Mosenkis, A.; Flaherty, K.T.; Gallagher, M.; Stevenson, J.P.; Townsend, R.R.; O'Dwyer, P.J. Mechanisms of hypertension associated with BAY 43-9006. J. Clin. Oncol. 2006, 24, 1363-1369.
64. Alper, O.; Bergmann-Leitner, E.S.; Bennett, T.A.; Hacker, N.F.; Stromberg, K.; Stetler- Stevenson, W.G. Epidermal growth factor receptor signaling and the invasive phenotype of ovarian carcinoma cells. J. Nat. Cancer Inst. 2001, 93, 1375-1384.
65. Skirnisdottir, I.; Sorbe, B.; Seidal, T. The growth factor receptors HER-2/neu and EGFR, their relationship, and their effects on the prognosis in early stage (FIGO I-II) epithelial ovarian carcinoma. Int. J. Gynecol. Cancer 2001, 11, 119-129.
66. Mendelsohn, J.; Baselga, J. Status of epidermal growth factor receptor antagonists in the biology and treatment of cancer. J. Clin. Oncol. 2003, 21, 2787-2799.
67. Goldstein, N.I.; Prewett, M.; Zuklys, K.; Rockwell, P.; Mendelsohn, J. Biological efficacy of a chimeric antibody to the epidermal growth factor receptor in a human tumor xenograft model. Clin. Cancer Res. 1995, 1, 1311-1318.
68. Seiden, M.V.; Burris, H.A.; Matulonis, U.; Hall, J.B.; Armstrong, D.K.; Speyer, J.; Weber, J.D.; Muggia, F. A phase II trial of EMD72000 (matuzumab), a humanized anti-EGFR monoclonal antibody, in patients with platinum-resistant ovarian and primary peritoneal malignancies. Gynecol. Oncol. 2007, 104, 727-731.
69. Calvo, E.; Tolcher, A.W.; Hammond, L.A.; Patnaik, A.; de Bono, J.S.; Eiseman, I.A.; Olson, S.C.; Lenehan, P.F.; McCreery, H.; Lorusso, P., et al. Administration of CI-1033, an Irreversible PanerbB Tyrosine Kinase Inhibitor, Is Feasible on a 7-Day On, 7-Day Off Schedule. Clin. Cancer Res. 2004, 10, 7112-7120.
70. Finkler, N.; Gordon, A.; Crozier, M.; Edwards, R.; Figueroa, J.; Garcia, A.; Hainsworth, J.; Irwin, D.; Silberman, S.; Allen, L., et al. Phase 2 Evaluation of OSI-774, a Potent Oral Antagonist of the EGFR-TK in Patients with Advanced Ovarian Carcinoma. J. Clin. Oncol. 2001, 20(Proc ASCO 2001), Abstr. 831.
71. Aghajanian, C.; Sabbatini, P.; Derosa, F.; Gerst, S.; Spriggs, D.R.; Dupont, J.; Hensley, M.L.; Pezzulli, S.; Konner, J.; Schilder, R.J. A Phase II Study of Cetuximab/Paclitaxel/Carboplatin for the Initial Treatment of Advanced Stage Ovarian, Primary Peritoneal, and Fallopian Tube Cancer. J. Clin. Oncol. 2005, 23(16S), Abstr. 2047.
72. Amado, R.G.; Wolf, M.; Peeters, M.; van Cutsem, E.; Siena, S.; Freeman, D.J.; Juan, T.; Sikorski, R.; Suggs, S.; Radinsky, R., et al. Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer. J. Clin. Oncol. 2008, 26, 1626-1634.
73. Shih, I.M.; Kurman, R.J. Ovarian tumorigenesis: a proposed model based on morphological and molecular genetic analysis. Am. J. Pathol 2004, 164, 1511-1518.
74. Schilder, R.J.; Sill, M.W.; Chen, X.; Darcy, K.M.; Decesare, S.L.; Lewandowski, G.; Lee, R.B.; Arciero, C.A.; Wu, H.; Godwin, A.K. Phase II study of gefitinib in patients with relapsed or persistent ovarian or primary peritoneal carcinoma and evaluation of epidermal growth factor receptor mutations and immunohistochemical expression: a Gynecologic Oncology Group Study. Clin. Cancer Res. 2005, 11, 5539-5548.
75. Bookman, M.A.; Darcy, K.M.; Clarke-Pearson, D.; Boothby, R.A.; Horowitz, I.R. Evaluation of monoclonal humanized anti-HER2 antibody, trastuzumab, in patients with recurrent or refractory ovarian or primary peritoneal carcinoma with overexpression of HER2: a phase II trial of the Gynecologic Oncology Group. J. Clin. Oncol. 2003, 21, 283-90.
76. Gordon, M.S.; Matei, D.; Aghajanian, C.; Matulonis, U.A.; Brewer, M.; Fleming, G.F.; Hainsworth, J.D.; Garcia, A.A.; Pegram, M.D.; Schilder, R.J., et al. Clinical activity of pertuzumab (rhuMAb 2C4), a HER dimerization inhibitor, in advanced ovarian cancer: potential predictive relationship with tumor HER2 activation status. J. Clin. Oncol. 2006, 24, 4324-4332.
77. Amler, L.; Makhija, S.; Januario, T.; Matulonis, U.A.; Strauss, A.; Dizon, D.S.; Sliwkowski, M.X.; Dolezal, M.; Tong, B.; Paton, V. HER pathway gene expression analysis in a phase II study of pertuzumab + gemcitabine vs. gemcitabine + placebo in patients with platinum-resistant epithelial ovarian cancer. J. Clin. Oncol. 2008, 26(15S), Abstr. 5522.
78. Schreiber, V.; Dantzer, F.; Ame, J.C.; de Murcia, G. Poly(ADP-ribose): novel functions for an old molecule. Nat Rev Mol Cell Biol 2006, 7, 517-528.
79. Ame, J.C.; Spenlehauer, C.; de Murcia, G. The PARP superfamily. Bioessays 2004, 26, 882-893.
80. Bryant, H.E.; Schultz, N.; Thomas, H.D.; Parker, K.M.; Flower, D.; Lopez, E.; Kyle, S.; Meuth, M.; Curtin, N.J.; Helleday, T. Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase. Nature 2005, 434, 913-917.
81. Farmer, H.; McCabe, N.; Lord, C.J.; Tutt, A.N.; Johnson, D.A.; Richardson, T.B.; Santarosa, M.; Dillon, K.J.; Hickson, I.; Knights, C., et al. Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy. Nature 2005, 434, 917-921.
82. Hay, T.; Jenkins, H.; Sansom, O.J.; Martin, N.M.; Smith, G.C.; Clarke, A.R. Efficient deletion of normal Brca2-deficient intestinal epithelium by poly(ADP-ribose) polymerase inhibition models potential prophylactic therapy. Cancer Res. 2005, 65, 10145-10148.
83. Fong, P.C.; Spicer, J.; Reade, S.; Reid, A.; Vidal, L.; Schellens, J.H.; Tutt, A.; Harris, P.A.; Kaye, S.; DeBono, J.S. Phase I pharmacokinetic (PK) and pharmacodynamic (PD) evaluation of a small molecule inhibitor of Poly ADP-Ribose Polymerase (PARP), KU-0059436 (Ku) in patients (p) with advanced tumours. J. Clin. Oncol. 2006, 24(18S), Abstr. 3022.
84. Tutt, A.N.; Lord, C.J.; McCabe, N.; Farmer, H.; Turner, N.; Martin, N.M.; Jackson, S.P.; Smith, G.C.; Ashworth, A. Exploiting the DNA repair defect in BRCA mutant cells in the design of new therapeutic strategies for cancer. Cold Spring Harb. Symp. Quant. Biol. 2005, 70, 139-148.
85. Fong, P.C.; Boss, D.S.; Carden, C.P.; Roelvink, M.; De Greve, J.; Gourley, C.M.; Carmichael, J.; De Bono, J.S.; Schellens, J.H.; Kaye, S.B. AZD2281 (KU-0059436), a PARP (poly ADP-ribose polymerase) inhibitor with single agent anticancer activity in patients with BRCA deficient ovarian cancer: Results from a phase I study. J. Clin. Oncol. 2008, 26(suppl), Abstr. 5510.
86. Audeh, M.W.; Penson, R.T.; Friedlander, M.; Powell, B.; Bell-McGuinn, K.M.; Scott, C.; Weitzel, J.N.; Carmichael, J.; Tutt, A. Phase II trial of the oral PARP inhibitor olaparib (AZD2281) in BRCA-deficient advanced ovarian cancer. J. Clin. Oncol. 2009, 27(15S), Abstr. 5500.
87. Turner, N.; Tutt, A.; Ashworth, A. Hallmarks of 'BRCAness' in sporadic cancers. Nat. Rev. Cancer 2004, 4, 814-819.
88. Press, J.Z.; De Luca, A.; Boyd, N.; Young, S.; Troussard, A.; Ridge, Y.; Kaurah, P.; Kalloger, S.E.; Blood, K.A.; Smith, M., et al. Ovarian carcinomas with genetic and epigenetic BRCA1 loss have distinct molecular abnormalities. BMC Cancer 2008, 8, 17.
89. Hennessy, B.T.; Smith, D.L.; Ram, P.T.; Lu, Y.; Mills, G.B. Exploiting the PI3K/AKT pathway for cancer drug discovery. Nat. Rev. Drug Discov. 2005, 4, 988-1004.
90. Meric-Bernstam, F.; Gonzalez-Angulo, A.M. Targeting the mTOR signaling network for cancer therapy. J. Clin. Oncol. 2009, 27, 2278-2287.
91. Shayesteh, L.; Lu, Y.; Kuo, W.L.; Baldocchi, R.; Godfrey, T.; Collins, C.; Pinkel, D.; Powell, B.; Mills, G.B.; Gray, J.W. PIK3CA is implicated as an oncogene in ovarian cancer. Nat. Genet. 1999, 21, 99-102.
92. Campbell, I.G.; Russell, S.E.; Choong, D.Y.; Montgomery, K.G.; Ciavarella, M.L.; Hooi, C.S.; Cristiano, B.E.; Pearson, R.B.; Phillips, W.A. Mutation of the PIK3CA gene in ovarian and breast cancer. Cancer Res. 2004, 64, 7678-7681.
93. Obata, K.; Morland, S.J.; Watson, R.H.; Hitchcock, A.; Chenevix-Trench, G.; Thomas, E.J.; Campbell, I.G. Frequent PTEN/MMAC mutations in endometrioid but not serous or mucinous epithelial ovarian tumors. Cancer Res. 1998, 58, 2095-2097.
94. Wolf, J.; Slomovitz, B.M. Novel biologic terapies for the treatment of endometrial cancer. Int. J. Gynecol. Cancer 2005, 15, 411.
95. Hay, N. The Akt-mTOR tango and its relevance to cancer. Cancer Cell 2005, 8, 179-83.
96. Altomare, D.A.; Wang, H.Q.; Skele, K.L.; De Rienzo, A.; Klein-Szanto, A.J.; Godwin, A.K.; Testa, J.R. AKT and mTOR phosphorylation is frequently detected in ovarian cancer and can be targeted to disrupt ovarian tumor cell growth. Oncogene 2004, 23, 5853-5857.
97. Trinh, X.B.; Tjalma, W.A.; Vermeulen, P.B.; van den Eynden, G.; van der Auwera, I.; van Laere, S.J.; Helleman, J.; Berns, E.M.; Dirix, L.Y.; van Dam, P.A. The VEGF pathway and the AKT/mTOR/p70S6K1 signalling pathway in human epithelial ovarian cancer. Br. J. Cancer 2009, 100, 971-978.
98. Xing, H.; Weng, D.; Chen, G.; Tao, W.; Zhu, T.; Yang, X.; Meng, L.; Wang, S.; Lu, Y.; Ma, D. Activation of fibronectin/PI-3K/Akt2 leads to chemoresistance to docetaxel by regulating survivin protein expression in ovarian and breast cancer cells. Cancer Lett. 2008, 261, 108-119.
99. Fraser, M.; Bai, T.; Tsang, B.K. Akt promotes cisplatin resistance in human ovarian cancer cells through inhibition of p53 phosphorylation and nuclear function. Int. J. Cancer 2008, 122, 534-546.
100. Mondesire, W.H.; Jian, W.; Zhang, H.; Ensor, J.; Hung, M.C.; Mills, G.B.; Meric-Bernstam, F. Targeting mammalian target of rapamycin synergistically enhances chemotherapy-induced cytotoxicity in breast cancer cells. Clin. Cancer Res. 2004, 10, 7031-7042.
101. Thomassin-Naggara, I.; Darai, E.; Cuenod, C.A.; Rouzier, R.; Callard, P.; Bazot, M. Dynamic contrast-enhanced magnetic resonance imaging: a useful tool for characterizing ovarian epithelial tumors. J. Magn. Reson. Imaging 2008, 28, 111-120.
102. Bast, R.C., Jr.; Klug, T.L.; St John, E.; Jenison, E.; Niloff, J.M.; Lazarus, H.; Berkowitz, R.S.; Leavitt, T.; Griffiths, C.T.; Parker, L., et al. A radioimmunoassay using a monoclonal antibody to monitor the course of epithelial ovarian cancer. N. Engl. J. Med. 1983, 309, 883-887.
103. Berek, J.S.; Schultes, B.C.; Nicodemus, C.F. Biologic and immunologic therapies for ovarian cancer. J. Clin. Oncol. 2003, 21(10S), 168s-174s.
104. Madiyalakan, R.; Sykes, T.R.; Dharampaul, S.; Sykes, C.J.; Baum, R.P.; Hör, G.; Noujaim, A.A. Antiidiotype induction therapy: evidence for the induction of immune response through the idiotype network in patients with ovarian cancer after administration of anti-CA125 murine monoclonal antibody B43.13. Hybridoma 1995, 14, 199-203.
105. Ehlen, T.G.; Hoskins, P.J.; Miller, D.; Whiteside, T.L.; Nicodemus, C.F.; Schultes, B.C.; Swenerton, K.D. A pilot phase 2 study of oregovomab murine monoclonal antibody to CA125 as an immunotherapeutic agent for recurrent ovarian cancer. Int. J. Gynecol. Cancer 2005, 15, 1023-1034.
106. Gordon, A.N.; Schultes, B.C.; Gallion, H.; Edwards, R.; Whiteside, T.L.; Cermak, J.M.; Nicodemus, C.F. CA125- and tumor-specific T-cell responses correlate with prolonged survival in oregovomab-treated recurrent ovarian cancer patients. Gynecol. Oncol 2004, 94, 340-351.
107. Berek, J.S.; Taylor, P.T.; Gordon, A.; Cunningham, M.J.; Finkler, N.; Orr, J., Jr.; Rivkin, S.; Schultes, B.C.; Whiteside, T.L.; Nicodemus, C.F. Randomized, placebo-controlled study of oregovomab for consolidation of clinical remission in patients with advanced ovarian cancer. J. Clin. Oncol. 2004, 22(17), 3507-3516.
108. Braly, P.; Chu, C.; Collins, Y.; Edwards, R.; Gordon, A.; McGuire, W.; Smith, L.M.; Nicodemus, C.; Method, M. Prospective evaluation of front-line chemo-immunotherapy (C-IT) with oregovomab (2 alternative dosing schedules) carboplatin-paclitaxel (C-P) in advanced ovarian cancer (OC). J. Clin. Oncol. 2007, 25(18S), Abstr. 3024.
109. Parsons, S.; Murawa, P.X.; Koralewski, P.; Kutarska, E.; Kolesnik, O.O.; Stroehlein, M.A.; Lahr, A.; Jaeger, M.; Heiss, M.M. Intraperitoneal treatment of malignant ascites due to epithelial tumors with catumaxomab, A phase II/III study. J. Clin. Oncol. 2008, 26(suppl), Abstr. 3000.
110. Elnakat, H.; Ratnam, M. Role of folate receptor genes in reproduction and related cancers. Front. Biosci. 2006, 11, 506-519.
111. Ebel, W.; Routhier, E.L.; Foley, B.; Jacob, S.; McDonough, J.M.; Patel, R.K.; Turchin, H.A.; Chao, Q.; Kline, J.B.; Old, L.J., et al. Preclinical evaluation of MORAb-003, a humanized monoclonal antibody antagonizing folate receptor-alpha. Cancer Immun. 2007, 7, 6.
112. Armstrong, D.K.; Bicher, A.; Coleman, R.L.; Gibbon, D.G.; Glenn, D.; Old, L.; Senzer, N.N.; Schneeweiss, A.; Verheijen, R.H.; White, A.J.; Weil, S. Exploratory phase II efficacy study of MORAb-003, a monoclonal antibody against folate receptor alpha, in platinum-sensitive ovarian cancer in first relapse. J. Clin. Oncol. 2008, 26(suppl), Abstr. 5500.
113. Gibbs, D.D.; Theti, D.S.; Wood, N.; Green, M.; Raynaud, F.; Valenti, M.; Forster, M.D.; Mitchell, F.; Bavetsias, V.; Henderson, E., et al. BGC 945, a novel tumor-selective thymidylate synthase inhibitor targeted to alpha-folate receptor-overexpressing tumors. Cancer Res. 2005, 65, 11721-11728.
114. Weinstein, I.B.; Joe, A. Oncogene addiction. Cancer Res. 2008, 68, 3077-3080.
115. Lacroix, L.; Pautier, P.; Duvillard, P.; Motté, N.; Saulnier, P.; Bidart, J.M.; Soria, J.C. Response of ovarian carcinomas to gefitinib-carboplatin-paclitaxel combination is not associated with EGFR kinase domain somatic mutations. Int. J. Cancer 2006, 118, 1068-1069.
116. Stella, G.; Rojas Llimpe, F.L.; Barone, C.; Falcone, A.; Di Fabio, F.; Lamba, S.; Martoni, A.A.; Siena, S.; Bardelli, A.; Pinto, C. KRAS and BRAF mutational status and response to cetuximab combination therapy in advanced gastric cancer (GC) patients. 2009 Gastrointestinal Cancers Symposium, San Francisco, CA, USA, 15-17 January 2009; Abstr. 34.
117. Zhang, S.; Balch, C.; Chan, M.W.; Lai, H.C.; Matei, D.; Schilder, J.M.; Yan, P.S.; Huang, T.H.; Nephew, K.P. Identification and characterization of ovarian cancer-initiating cells from primary human tumors. Cancer Res. 2008, 68, 4311-4320.
118. Marrer, E.; Dieterle, F. Biomarkers in oncology drug development: rescuers or troublemakers? Expert Opin. Drug Metab. Toxicol. 2008, 4, 1391-1402.
119. Agus, D.B.; Gordon, M.S.; Taylor, C.; Natale, R.B.; Karlan, B.; Mendelson, D.S.; Press, M.F.; Allison, D.E.; Sliwkowski, M.X.; Lieberman, G., et al. Phase I clinical study of pertuzumab, a novel HER dimerization inhibitor, in patients with advanced cancer. J. Clin. Oncol. 2005, 23, 2534-2543.
120. Vasey, P.; Kaye, S.; Paul, J.; Rustin, G.; Wilson, R.; Guastalla, J.P.; Pujade-Lauraine, E.; Gore, M.; Gabra, H.; Carty, K. A phase Ib trial of erlotinib (E) in combination with docetaxel (D) and carboplatin (C) in untreated ovarian, fallopian tube and primary peritoneal cancers J. Clin. Oncol. 2004, 22(14S), Abstr. 5017.
121. Blank, S.V.; Curtin, J.P.; Goldman, N.A.; Runowicz, C.D.; Speyer, J.L.; Tiersten, A.D.; Dancey, J.; Wadler, S.; Muggia, F.M. Report of first-stage accrual for NCI 5886, a phase II study of erlotinib, carboplatin and paclitaxel as first-line treatment of ovarian cancer. J. Clin. Oncol. 2006, 24(18S), Abstr. 5076.
122. Slomovitz, B.M.; Coleman, R.L.; Levenback, C.; Jung, M.; Gershenson, D.M.; Wolf, J. Phase I study of weekly topotecan and gefitinib in patients with platinum-resistant ovarian, peritoneal, or fallopian tube cancer J. Clin. Oncol. 2006, 24(18S), Abstr. 5090.
123. Hariprasad, R.; Kumar, L.; Patnaik, R.; Gupta, A.; Kumar, S. Maintenance therapy in epithelial ovarian cancer (EOC): Could EGFR inhibitor- gefitinib be a candidate drug? A pilot study. J. Clin. Oncol. 2006, 24(18S), Abstr. 15046.
124. Mavroudis, D.; Efstathiou, E.; Polyzos, A.; Athanasiadis, A.; Milaki, G.; Kastritis, E.; Kalykaki, A.; Saridaki, Z.; Dimopoulos, A.; Georgoulias, V. A phase I-II trial of gefitinib in combination with vinorelbine and oxaliplatin as salvage therapy in women with advanced ovarian cancer (AOC). J. Clin. Oncol. 2004, 22(14S), Abstr. 5020.
125. Krasner, C.N.; Debernardo, R.L.; Findley, M.; Penson, R.; Matulonis, U.; Atkinson, T.; Roche, M.; Seiden, M.V. Phase II trial of anastrazole in combination with gefitinib in women with asymptomatic mullerian cancer J. Clin. Oncol. 2005, 23(16S), Abstr. 5063.
126. Minami, H.; Nakagawa, K.; Kawada, K.; Mukai, H.; Tahara, M.; Kurata, T.; Uejima, H.; Nogami, T.; Sasaki, Y.; Fukuoka, M. A phase I study of GW572016 in patients with solid tumors J. Clin. Oncol. 2004, 22(14S), Abstr. 3048
127. Campos, S.M.; Seiden, M.V.; Oza, A.; Plante, M.; Potkul, R.; Hamid, O.; Lenehan, P.; Kaldjian, E.; Jordan, C.; Hirte, H. A phase 2, single agent study of CI-1033 administered at two doses in ovarian cancer patients who failed platinum therapy J. Clin. Oncol. 2004, 22(14S), Abstr. 5054